share_log

Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award

Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award

Passage Bio宣佈第三屆年度山田太智獎學金獲得者
GlobeNewswire ·  05/21 20:00

PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of its Tachi Yamada Scholarship award.

費城,2024年5月21日(GLOBE NEWSWIRE)——專注於改善神經退行性疾病患者生活的臨床階段遺傳藥物公司Passage Bio, Inc.(納斯達克股票代碼:PASG)今天宣佈,德雷塞爾大學二年級學生嘉莉·戈登是其山田太極獎學金的第三位獲得者。

The scholarship honors the legacy of Dr. Tachi Yamada, co-founder and former Chairman of the Passage Bio Board of Directors and is open to students enrolled in life sciences programs at four-year colleges and universities in Pennsylvania who seek a career in the life sciences industry.

該獎學金旨在表彰Passage Bio董事會聯合創始人兼前主席山田太智博士的遺產,向在賓夕法尼亞州四年制學院和大學就讀生命科學課程並尋求生命科學行業職業的學生開放。

Carrie is pursuing a Bachelor of Science degree in Biological Science with a minor in Neuroscience. She has excelled in her academic studies as she pursues a career in medicine and has developed a particular interest in neurology, conducting preclinical research on the neural morphology of genes related to autism spectrum disorder. Carrie was selected to the Students Tackling Advanced Research, or STAR, Scholars program and the Aspire Scholars program and hopes to combine her passions for volunteerism and medicine to provide healthcare to underserved communities.

嘉莉正在攻讀生物科學理學學士學位,輔修神經科學。在從事醫學事業的過程中,她在學術研究方面表現出色,並對神經病學產生了特別的興趣,對自閉症譜系障礙相關基因的神經形態學進行了臨床前研究。嘉莉被選入 “學生參與高級研究”(STAR)、學者計劃和Aspire Scholars項目,她希望將自己對志願服務和醫學的熱情結合起來,爲服務不足的社區提供醫療保健。

In addition to her academic and research interests, Carrie is a member of Drexel's chamber strings and serves on the board of the university's Club for Students with Visible and Invisible Disabilities.

除了學術和研究興趣外,嘉莉還是德雷塞爾室內樂團的成員,也是該大學可見和隱形殘疾學生俱樂部的董事會成員。

"The Passage Bio team is excited to award the third annual Tachi Yamada Scholarship to Carrie Gordon. Carrie's first-hand experiences with the healthcare system have forged her passion for pursuing a career in medicine and giving back to those in need. She exemplifies the qualities this scholarship program seeks to honor and is a worthy recipient of this award," said William Chou, M.D., president and chief executive officer of Passage Bio. "We are honored to support Carrie in her pursuits and look forward to her continued achievements."

“Passage Bio團隊很高興向嘉莉·戈登頒發第三屆年度山田太智獎學金。嘉莉在醫療保健系統方面的親身經歷激發了她追求醫學事業和回饋有需要的人的熱情。她體現了該獎學金計劃力求表彰的品質,是該獎項的當之無愧的獲得者。” Passage Bio總裁兼首席執行官周偉倫醫學博士說。“我們很榮幸能支持嘉莉的追求,並期待她繼續取得成就。”

Through the scholarship, Carrie will receive financial assistance towards college-related expenses and will be matched with a Passage Bio mentor for professional growth opportunities over the two-year scholarship period.

通過該獎學金,嘉莉將獲得與大學相關的費用經濟援助,並將與Passage Bio導師配對,在爲期兩年的獎學金期內獲得職業發展機會。

Passage Bio first announced its plans to launch the annual Tachi Yamada Scholarship Program in October 2021 to continue the legacy of Tadataka (Tachi) Yamada, M.D., a visionary biopharma industry leader who passed away in August 2021. Dr. Yamada had a life-long devotion to mentoring and building the next generation of scientists.

Passage Bio於2021年10月首次宣佈計劃啓動年度山田太智獎學金計劃,以延續山田忠隆(Tachi)醫學博士的遺產,他是一位富有遠見的生物製藥行業領導者,於2021年8月去世。山田博士一生致力於指導和培養下一代科學家。

About Passage Bio

Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio's lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.

Passage Bio(納斯達克股票代碼:PASG)是一家臨床階段的基因藥物公司,其使命是改善神經退行性疾病患者的生活。我們的主要重點是開發和推進尖端的一次性療法,旨在針對這些疾病的潛在病理。Passage Bio的主要候選產品 PBFT02 旨在通過提高程序蛋白水平來恢復溶酶體功能和減緩疾病進展來治療神經退行性疾病,包括額葉癡呆。

To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: .

要了解有關Passage Bio的更多信息以及我們對保護患者和家屬免受神經退行性疾病損失的堅定承諾, 請訪問:.

For further information, please contact:

欲了解更多信息,請聯繫:

Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com

投資者:
斯圖爾特·亨
通道生物
267.866.0114
shenderson@passagebio.com

Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
MikeBeyer@sambrown.com

媒體:
邁克·拜爾
山姆·布朗公司醫療保健通訊
312.961.2502
MikeBeyer@sambrown.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論